References of "Bours, Vincent"
     in
Bookmark and Share    
See detailTSH-secreting pituitary adenoma in a male patient with a novel missense AIP mutation
Fajardo Montanana, C.; Daly, Adrian ULg; Tichomirova, M. A. et al

in The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009)

Detailed reference viewed: 17 (1 ULg)
See detailHigh Incidence of AIP mutations in sporadic pituitary adenomas in young patients with macroadenomas
Tichomirova, M. A.; Daly, Adrian ULg; Barlier, A. et al

in The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009)

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailEarly termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.
Robe, Pierre ULg; Martin, Didier ULg; Nguyen-Khac, Minh-Tuan ULg et al

in BMC Cancer (2009), 9

BACKGROUND: Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas. As it presents an ... [more ▼]

BACKGROUND: Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas. As it presents an excellent safety profile, we initiated a phase 1/2 clinical study of this anti-inflammatory drug for the treatment of recurrent WHO grade 3 and 4 astrocytic gliomas in adults. METHODS: 10 patients with advanced recurrent anaplastic astrocytoma (n = 2) or glioblastoma (n = 8) aged 32-62 years were recruited prior to the planned interim analysis of the study. Subjects were randomly assigned to daily doses of 1.5, 3, 4.5, or 6 grams of oral sulfasalazine, and treated until clinical or radiological evidence of disease progression or the development of serious or unbearable side effects. Primary endpoints were the evaluation of toxicities according to the CTCAE v.3.0, and the observation of radiological tumor responses based on MacDonald criteria. RESULTS: No clinical response was observed. One tumor remained stable for 2 months with sulfasalazine treatment, at the lowest daily dose of the drug. The median progression-free survival was 32 days. Side effects were common, as all patients developed grade 1-3 adverse events (mean: 7.2/patient), four patients developed grade 4 toxicity. Two patients died while on treatment or shortly after its discontinuation. CONCLUSION: Although the proper influence of sulfasalazine treatment on patient outcome was difficult to ascertain in these debilitated patients with a large tumor burden (median KPS = 50), ISRCTN45828668 was terminated after its interim analysis. This study urges to exert cautiousness in future trials of Sulfasalazine for the treatment of malignant gliomas. TRIAL REGISTRATION: Current Controlled Trials ISRCTN45828668. [less ▲]

Detailed reference viewed: 45 (13 ULg)
Full Text
Peer Reviewed
See detailThe proapoptotic C16-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells.
Renert, Anne-Francoise; Leprince, Pierre ULg; Dieu, Marc et al

in Journal of Proteome Research (2009), 8(10), 4810-22

Ceramides are central molecules in sphingolipid metabolism. They are involved in the regulation of cancer-cell growth, differentiation, senescence and apoptosis. To better understand how these secondary ... [more ▼]

Ceramides are central molecules in sphingolipid metabolism. They are involved in the regulation of cancer-cell growth, differentiation, senescence and apoptosis. To better understand how these secondary messengers induce their biological effects, adenocarcinoma cells (HCT116) were treated with exogenous long-chain ceramides (C16-ceramide) in order to mimic endogenous sphingolipids. This treatment induced a decrease of cell viability partly due to apoptosis as shown by PARP cleavage and a decrease of pro-caspase 3. Two-dimensional differential in-gel electrophoresis (2D-DIGE) revealed the differential expression of 51 proteins in response to C16-ceramide. These proteins are notably involved in cell proliferation, apoptosis, protein transport and transcriptional regulation. Among them, the cell death-promoting factor Btf was found to be implicated in the apoptotic signal triggered by ceramide. In adenocarcinoma cells, Btf regulates apoptosis related proteins such as Mdm2, p53, BAX and pBcl-2 and thus plays an important role in the ceramide mediated cell death. These findings bring new insight into the proapoptotic ceramide-dependent signaling pathway. [less ▲]

Detailed reference viewed: 79 (23 ULg)
Full Text
Peer Reviewed
See detailA P2X Ion Channel-triggered NF-{kappa}B Pathway Enhances TNF-{alpha}-induced IL-8 Expression in Airway Epithelial Cells.
Theatre, Emilie ULg; Bours, Vincent ULg; Oury, Cécile ULg

in American Journal of Respiratory Cell and Molecular Biology (2009)

Extracellular ATP, acting at P2Y and P2X receptors, has recently been shown to contribute to airway inflammation. Using different epithelial cell models, this study shows that ATP promotes TNF-alpha ... [more ▼]

Extracellular ATP, acting at P2Y and P2X receptors, has recently been shown to contribute to airway inflammation. Using different epithelial cell models, this study shows that ATP promotes TNF-alpha-elicited IL-8 expression through P2X ion channel-triggered Ca(2+) entry, leading to CaMK-dependent IKK activation and binding of active p65 to IL-8 gene promoter. [less ▲]

Detailed reference viewed: 82 (29 ULg)
Full Text
Peer Reviewed
See detailP2X1 Ion Channels Promote Neutrophil Chemotaxis through Rho Kinase Activation
Lecut, Christelle ULg; Frederix, Kim ULg; Johnson, Daniel M et al

in Journal of Immunology (2009)

This study shows that activation of P2X1 ion channels by ATP promotes neutrophil chemotaxis, a process involving Rho kinase-dependent actomyosin-mediated contraction at the cell rear. These ion channels ... [more ▼]

This study shows that activation of P2X1 ion channels by ATP promotes neutrophil chemotaxis, a process involving Rho kinase-dependent actomyosin-mediated contraction at the cell rear. These ion channels may therefore play a significant role in host defense and inflammation. [less ▲]

Detailed reference viewed: 58 (20 ULg)
Full Text
Peer Reviewed
See detailDeletion of Xpter encompassing the SHOX gene and PAR1 region in familial patients with Leri-Weill Dyschondrosteosis syndrome.
Mutesa, L.; Vanbellinghen, Jean-François ULg; Hellin, Anne-Cécile ULg et al

in Genetic Counseling (Geneva, Switzerland) (2009), 20(1), 9-17

Heterozygote deletions or mutations of pseudoautosomal 1 region (PAR1) encompassing the short stature homeobox-containing (SHOX) gene cause Leri-Weill Dyschondrosteosis (LWD), which is a dominantly ... [more ▼]

Heterozygote deletions or mutations of pseudoautosomal 1 region (PAR1) encompassing the short stature homeobox-containing (SHOX) gene cause Leri-Weill Dyschondrosteosis (LWD), which is a dominantly inherited osteochondroplasia characterized by short stature with mesomelic shortening of the upper and lower limbs and Madelung deformity of the wrists. SHOX is expressed by both sex chromosomes in males and females and plays an important role in bone growth and development. Clinically, the LWD expression is variable and more severe in females than males due to sex differences in oestrogen levels. Here, we report two familial cases of LWD with a large Xp terminal deletion (approximately 943 kb) of distal PAR1 encompassing the SHOX gene. In addition, the proband had mental retardation which appeared to be from recessive inheritance in the family. [less ▲]

Detailed reference viewed: 41 (7 ULg)
Full Text
Peer Reviewed
See detailDiagnostic challenges of cystic fibrosis in patients of African origin.
Mutesa, Leon; Bours, Vincent ULg

in Journal of Tropical Pediatrics (2009), 55(5), 281-6

Detailed reference viewed: 24 (1 ULg)
Full Text
Peer Reviewed
See detailCaractérisation clinique et génétique des adénomes hypophysaires familiaux isolés (FIPA).
Beckers, Albert ULg; Apetrii, P.; Daly, Adrian ULg et al

in Revue Médicale de Liège (2009), 64(S1), 15-19

Pituitary adenomas are common brain tumours at autopsy and radiological series of unselected population. Historically, few epidemiologic data regarding the prevalence of clinically apparent pituitary ... [more ▼]

Pituitary adenomas are common brain tumours at autopsy and radiological series of unselected population. Historically, few epidemiologic data regarding the prevalence of clinically apparent pituitary adenomas have been available. Recently, a cross-sectional study conducted in Liege, Belgium, noted that clinically-apparent pituitary adenomas occurred with a prevalence of 1:1064 inhabitants, which is 3.5-5 times the previously reported prevalence. Pituitary adenomas occur predominantly as sporadic tumors, but also in a familial setting or associated to some familial/isolated tumoral syndromes. The recent characterization of the novel clinical entity FIPA (Familial Isolated Pituitary Adenomas) increased the prevalence of familial pituitary adenomas which account now for about 5% of pituitary tumors. Distinct genetic mechanisms are continuously identified and increase our understanding of the complex clinical presentation and sometimes unpredictable evolution of pituitary adenomas. [less ▲]

Detailed reference viewed: 102 (7 ULg)
See detailAn international, collaborative study of disease characteristics and response to therapy in 60 pituitary adenoma patients with Aryl Hydrocarbon Receptor Interacting
Tikhomirova, M.; Daly, Adrian ULg; Jaffrain-Réa, M. L. et al

in 18th Meeting of the Belgian Endocrine and Metabolic societies : Bruxelles, 25 octobre 2008 (2008, October)

Detailed reference viewed: 16 (5 ULg)
See detailCyclin dependant kinase inhibitor 1B (CDKN1B) gene mutations in familial isolated pituitary adenomas (FIPA) : Analysis in 84 families
Apetrii, P.; Tikhomirova, M.; Daly, Adrian ULg et al

in 18th Meeting of the Belgian Endocrine and Metabolic societies : Bruxelles, 25 octobre 2008 (2008, October)

Detailed reference viewed: 10 (0 ULg)
See detailAn International, Collaborative Study of the Disease Characteristics and Response to Therapy in 60 Pituitary Adenoma Patients with Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations
Daly, Adrian ULg; Tichomirowa, M. A.; Ebeling, T. M. L. et al

in ENDO 2008: 90th Annual Meeting of the Endocrine Society - Abstract book (2008)

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailContribution of ATP-gated P2X1 ion channels to the control of neutrophil chemotaxis.
Lecut, Christelle ULg; Frederix, Kim ULg; Johnson, Daniel et al

in Purinergic Signalling (2008), 4

Detailed reference viewed: 16 (5 ULg)
See detailOccurrence of AIP Mutations in Sporidic Pituitary Adenomas and Familial Isolated Pituitary Adenomas Kindreds in Valencia, Spain
Fajardo Montanaña, C.; Daly, Adrian ULg; Tichomirowa, M. A. et al

in ENDO 2008: 90th Annual Meeting of the Endocrine Society - Abstract book (2008)

Detailed reference viewed: 13 (0 ULg)
See detailGenetic Causes of Pituitary Adenmas; Focus on the Roe of AIF Status in Multiple Tumor Types
Ansaneli Naves, L.; Ferreira Azevedo, M.; Faria de Castro, L. et al

in ENDO 2008: 90th Annual Meeting of the Endocrine Society - Abstract book (2008)

Detailed reference viewed: 5 (0 ULg)
See detailAryl Hydrocarbon Receptor interacting Protein Gene Mutations in Bulgarian FIPA and Young Sporadic Pituitary Adenoma Patients
Yaneva, M.; Daly, Adrian ULg; Tichomirowa, M. A. et al

in ENDO 2008: 90th Annual Meeting of the Endocrine Society - Abstract book (2008)

Detailed reference viewed: 24 (0 ULg)
Full Text
Peer Reviewed
See detailNewborn Screening for Sickle Cell Disease Using Tandem Mass Spectrometry
Boemer, François ULg; Ketelslegers, Olivier; Minon, Jean-Marc et al

in Clinical Chemistry (2008), 54(12), 2036-2041

BACKGROUND: Neonatal screening programs for sickle cell disease are now widespread in North American and European countries. Most programs apply isoelectric focusing or HPLC to detect hemoglobin variants ... [more ▼]

BACKGROUND: Neonatal screening programs for sickle cell disease are now widespread in North American and European countries. Most programs apply isoelectric focusing or HPLC to detect hemoglobin variants. Because tandem mass spectrometry (MS/MS) is being used for screening of inherited metabolic disorders and allows protein identification, it was worth testing for hemoglobinopathy screening. METHODS: We minimized sample preparation and analysis times by avoiding prior purification, derivatization, or separation. We developed a tryptic digestion methodology to screen for the main clinically important variants (HbS, HbC, and HbE) and beta-thalassemia. To ensure proper discrimination between homozygote and heterozygote variants, we selected 4 transitions with good signal intensities for each specific peptide and calculated variant/HbA ratios for each. Method validation included intra- and interseries variability, carryover, and limit of detection. We also performed a comparative study with isoelectric focusing results on 2082 specimens. RESULTS: Intraassay imprecision values (CVs) varied between 2.5% and 30.7%. Interassay CVs were between 6.3% and 23.6%. Carryover was <0.03%, and the limit of detection was fixed at 1% of HbS. According to the MS/MS settings (detection of HbS, HbC, HbE, and beta-globin production defects), the comparative study did not yield any discrepant results between the 2 techniques. CONCLUSIONS: MS/MS is a reliable method for hemoglobinopathy neonatal screening. [less ▲]

Detailed reference viewed: 74 (13 ULg)